Quarterly ResultMay 15, 2026, 04:29 PM
Yubo International Biotech Q1 Net Loss $(295K); Zero Revenue
AI Summary
Yubo International Biotech Ltd. reported a net loss of $(295,026) for the first quarter ended March 31, 2026, an improvement from a net loss of $(467,318) in the prior-year period. The company continued to report zero revenue from sales of products and services. Operating expenses decreased to $289,274, down from $467,299 year-over-year. The company's total assets declined to $709,872, while total liabilities increased to $3,019,451, resulting in a growing shareholders' deficit of $(2,309,579).
Key Highlights
- Q1 2026 net loss was $(295,026), an improvement from $(467,318) in Q1 2025.
- Revenue from sales of products and services remained $0 for Q1 2026 and Q1 2025.
- Operating expenses decreased to $289,274 in Q1 2026 from $467,299 in Q1 2025.
- Total assets decreased to $709,872 as of March 31, 2026, from $847,095 at December 31, 2025.
- Total liabilities increased to $3,019,451 as of March 31, 2026, from $2,791,297 at December 31, 2025.
- Shareholders' deficit grew to $(2,309,579) as of March 31, 2026, from $(1,944,202) at December 31, 2025.
- Cash and cash equivalents stood at $10,382 as of March 31, 2026.
- Net cash used in operating activities was $(207,157) in Q1 2026.
Price Impact
More from YBGJ